VYD2311's Superior Safety in Phase 3 LIBERTY Paves Way for BLA Filing
IVVD sits 83% above its 52-week low of $0.528 on elevated volume (2.6× avg).
Summary
Positive Phase 3 LIBERTY data show VYD2311 has superior safety and tolerability versus an mRNA COVID-19 vaccine, and Invivyd plans to file a BLA via Accelerated Approval with DECLARATION data expected in October 2026.
Key Events · Product Development and Regulatory · IVVD
-
VYD2311 Meets All LIBERTY Endpoints
Across the 6-day window, VYD2311 produced a 56.5% rate of TEAE/ISR/hypersensitivity versus 91.4% for the mRNA vaccine (p<0.0001), and the advantage persisted through 56 days at 60.9% versus 91.4% (p<0.0001). No hypersensitivity or anaphylaxis was observed in any arm.
-
Combination Arm Shows No Interference
When co-administered with an mRNA vaccine, VYD2311 boosted neutralizing titers by roughly 2.5x over 56 days without immunologic interference, suggesting it could improve vaccine safety and efficacy profiles.
-
BLA Submission via Accelerated Approval
Following a recent Type C meeting with the FDA, the company intends to submit a BLA for VYD2311 through the Accelerated Approval Program, leaning on data from DECLARATION and LIBERTY.
-
DECLARATION Data Expected October 2026
Topline safety and immunogenicity results from the DECLARATION pivotal study are slated for October 2026; clinical efficacy events will stay blinded for post-approval confirmatory analysis.
Analysis · IVVD · Life Sciences
The Phase 3 LIBERTY study delivered a decisive win for Invivyd's VYD2311 monoclonal antibody, which met all primary and secondary endpoints with clinically and statistically superior safety and tolerability versus an mRNA COVID-19 vaccine. Adverse events occurred in 56.5% of subjects receiving VYD2311 compared with 91.4% for the mRNA vaccine over 6 days (p<0.0001), and the benefit held through 56 days. With these results in hand, the company is moving toward a Biologics License Application under the FDA's Accelerated Approval pathway, and topline safety and immunogenicity data from the DECLARATION study are expected in October 2026. For a company facing going concern doubt, a Nasdaq delisting notice, and the impending loss of its only authorized product's EUA, this positive Phase 3 data and a clear regulatory path could fundamentally change its survival outlook.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IVVD was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $280M. The 52-week trading range was $0.53 to $3.07. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.